| Qantas Airways Limited (QAN) ORDINARY FULLY PAID |
Industrials |
$15,964 |
Qantas Group HY25 Appendix 4D and Interim Financial Report
|
27 Feb 2025 8:24AM |
$8.890 |
$10.550 |
risen by
18.67%
|
|
QAN - Price-sensitive ASX Announcement
Full Release
Key Points
- Underlying profit before tax increased by $140 million compared to the previous year.
- Statutory profit after tax rose to $923 million.
- Total revenue for the half-year was $12,129 million, up 9.0% from the previous year.
- Domestic operations reported an underlying EBIT of $647 million.
- International operations performed strongly with an underlying EBIT of $327 million.
- Strong demand in corporate and leisure travel supported revenue growth.
- The Group maintained focus on fleet renewal and customer experience enhancements.
- The Board announced a base dividend of $250 million and an additional special dividend of $150 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Coles Group Limited (COL) ORDINARY FULLY PAID |
Consumer Staple |
$28,722 |
Dividend/Distribution - COL
|
27 Feb 2025 8:24AM |
$19.690 |
$21.400 |
risen by
8.68%
|
|
| Pacific Smiles Group Limited (PSQ) ORDINARY FULLY PAID |
Health Care |
$352 |
PSQ FY25 Half Year Results Presentation
|
27 Feb 2025 8:23AM |
$1.960 |
$2.180 |
risen by
11.22%
|
|
PSQ - Price-sensitive ASX Announcement
Full Release
Key Points
- 9.0% increase in patient fees year-over-year to $160.3 million
- Underlying net profit after tax increased by 51.5% to $6.7 million
- Strong operational efficiencies led to improved financial metrics
- Declining cancellation rates indicating better patient communication
- Healthy net cash position of $8.1 million, debt-free
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Alcidion Group Limited (ALC) ORDINARY FULLY PAID |
Health Care |
$148 |
H1 FY25 Results Release
|
27 Feb 2025 8:23AM |
$0.090 |
$0.110 |
risen by
22.22%
|
|
ALC - Price-sensitive ASX Announcement
Full Release
Key Points
- H1 FY25 revenue of $17.6 million, a 7% decrease from pcp.
- Underlying EBITDA improved to $0.5 million, up $3.3 million from last year.
- New contracts totaling $61.3 million year-to-date, including a significant contract in Wales.
- Contracted revenue for FY25 estimated to be at least $39.5 million.
- Positive EBITDA and cash flow results anticipated for full year FY25.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pacific Smiles Group Limited (PSQ) ORDINARY FULLY PAID |
Health Care |
$352 |
PSQ announces Half Year Results to 31 December 2024
|
27 Feb 2025 8:23AM |
$1.960 |
$2.180 |
risen by
11.22%
|
|
PSQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Patient Fees of $160.3m, up 9.0% vs pcp
- Group Revenue of $99.0m, up 10.0% vs pcp
- Underlying EBITDA of $16.3m, up 16.8% vs pcp
- Underlying NPAT of $6.7m, compared with $4.4m in the pcp
- Total Pacific Smiles centres of 126, with two closures in 1H25
- Capital expenditure for the period of $3.2m, higher than the $1.8m reported in 1H24
- No interim dividend declared for FY25
- Patient satisfaction remains high with a net promoter score of 90
- Full year guidance re-affirmed for patient fees in the range of $310m to $318m
- Management focused on growth and maintaining a positive culture
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$6,877 |
2024 Full Year Investor Reference Pack
|
27 Feb 2025 8:22AM |
$5.070 |
$4.740 |
fallen by
6.51%
|
|
ALX - Price-sensitive ASX Announcement
Full Release
Key Points
- The Investor Reference Pack supplements the Financial Report of Atlas Arteria for the year ended 31 December 2024.
- Atlas Arteria operates toll roads in France, Germany, and the US, with an average portfolio concession life of around 18 years.
- The company has a 30.82% interest in the APRR toll road group in France.
- Atlas Arteria owns a 100% economic interest in the Dulles Greenway and the Warnow Tunnel.
- The APRR and AREA tolls escalate annually based on French CPI and government agreements.
- The Pack provides a detailed analysis of each business within the Atlas Arteria portfolio.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ramsay Health Care Limited (RHC) ORDINARY FULLY PAID |
Health Care |
$8,751 |
Dividend/Distribution - RHC
|
27 Feb 2025 8:22AM |
$33.870 |
$37.910 |
risen by
11.93%
|
|
| Alcidion Group Limited (ALC) ORDINARY FULLY PAID |
Health Care |
$148 |
H1 FY25 Appendix 4D and Half Year Report
|
27 Feb 2025 8:22AM |
$0.090 |
$0.110 |
risen by
22.22%
|
|
ALC - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue of $17,638K, a 7.5% decrease from the previous year.
- Gross profit of $15,366K, down 8.1% from the prior corresponding period.
- Loss after income tax improved to $889K from a loss of $4,336K.
- Underlying EBITDA profit of $541K, improving from a loss of $2,788K.
- Strategic restructuring has led to decreased employee benefits expenses.
- Alcidion signed significant new contracts expected to enhance future revenues.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Mach7 Technologies Limited (M7T) ORDINARY FULLY PAID |
Health Care |
$82 |
First Half FY25 Result Presentation
|
27 Feb 2025 8:21AM |
$0.440 |
$0.350 |
fallen by
20.45%
|
|
M7T - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue of A$17.7M, up 33% on prior corresponding period.
- Recurring revenue of A$12.6M, up 28%, accounting for 71% of total revenue.
- Operating expenses increased by 15% to A$15.8M.
- Positive EBITDA of A$0.8M, an improvement from the loss of A$1.6M in H1 FY24.
- Cash balance of A$23.6M at 31 December 2024, up 4% from the previous year.
- No debt reported by Mach7 Technologies.
- On-market share buy-back program announced for up to A$5M expected to commence in March 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Coles Group Limited (COL) ORDINARY FULLY PAID |
Consumer Staple |
$28,722 |
Half Yearly Report and Accounts
|
27 Feb 2025 8:21AM |
$19.690 |
$21.400 |
risen by
8.68%
|
|
COL - Price-sensitive ASX Announcement
Full Release
Key Points
- Sales revenue increased by 3.7% to $23,106 million.
- Earnings before interest and tax (EBIT) rose by 2.4% to $1,082 million.
- Net profit attributable to members decreased by 2.2% to $576 million.
- An interim dividend of 37.0 cents per share has been declared.
- The payment date for the interim dividend is March 27, 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Mach7 Technologies Limited (M7T) ORDINARY FULLY PAID |
Health Care |
$82 |
First Half FY25 Result
|
27 Feb 2025 8:20AM |
$0.440 |
$0.350 |
fallen by
20.45%
|
|
M7T - Price-sensitive ASX Announcement
Full Release
Key Points
- CARR of A$31.8M at 31 Dec 2024, up 19% on PCP
- ARR run rate of A$25.1M at 31 Dec 2024, up 35% on PCP
- Total revenue of A$17.7M, up 33% on PCP
- OPEX growth of 15% on PCP
- Cash of A$23.6M at 31 Dec 2024, up 4% on PCP
- On-market share buy-back of up to A$5M expected to commence on 3 Mar 2025
- Mach7 reaffirms FY25 guidance for 15-25% growth in CARR and revenue on PCP
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$6,877 |
2024 Full Year Results Presentation
|
27 Feb 2025 8:20AM |
$5.070 |
$4.740 |
fallen by
6.51%
|
|
ALX - Price-sensitive ASX Announcement
Full Release
Key Points
- Net profit after tax: $275.3m, +7.4% vs 2023
- Proportional toll revenue: $1,838.7m, +5.1% vs 2023
- Proportional EBITDA: $1,381.1m, +0.4% vs 2023
- Operating free cash flow: $527.1m, +16.0% vs 2023
- Distributions per security: 40.0 cps, unchanged from 2023
- Traffic increased on Dulles Greenway by 5.9% and Warnow Tunnel by 5.6%
- Toll revenue for Warnow Tunnel rose by 14.2%
- Toll revenue for Dulles Greenway increased by 6.9%
- APRR experienced a 0.4% increase in traffic overall
- Execution of capital management initiatives to optimize free cash flow.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Swoop Holdings Limited (SWP) ORDINARY FULLY PAID |
Communication Services |
$48 |
Half Yearly Report and Accounts
|
27 Feb 2025 8:20AM |
$0.165 |
$0.155 |
fallen by
6.06%
|
|
SWP - Price-sensitive ASX Announcement
Full Release
Key Points
- Swoop Holdings Limited reported increased production and revenue for the half-year ending 31 December 2024.
- The average realised gold price saw significant growth, contributing to revenue enhancement.
- Operational efficiencies were noted with effective cost management strategies implemented.
- Developments in the Hemi Project are on track to create a low-cost, long-life gold mine.
- The report emphasizes adherence to environmental and community standards during operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Rio Tinto Limited (RIO) ORDINARY FULLY PAID |
Materials |
$59,332 |
Appendix 3Y - Dean Dalla Valle
|
27 Feb 2025 8:19AM |
$115.020 |
$159.570 |
risen by
38.73%
|
|
| Clearview Wealth Limited (CVW) ORDINARY FULLY PAID |
Financials |
$342 |
CVW HY25 Investor Presentation
|
27 Feb 2025 8:19AM |
$0.385 |
$0.545 |
risen by
41.56%
|
|
CVW - Price-sensitive ASX Announcement
Full Release
Key Points
- Life Insurance Underlying NPAT of $15.2 million
- Share buyback of up to 10% of share capital planned
- Gross premiums increased by 8% to $191.4 million
- Embedded Value rose by 9.5% to $525.7 million
- Claims loss of $6.2 million in Q1 FY25 considered an outlier
- Ongoing technology transformation expected to complete in H1 FY26
- Market share in new business retained at 10.6%
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Antilles Gold Limited (AAU) ORDINARY FULLY PAID |
Materials |
$40 |
Antimony Production a Major Factor for the La Demajagua Mine
|
27 Feb 2025 8:19AM |
$0.005 |
$0.013 |
risen by
160%
|
|
| National Australia Bank Limited (NAB) ORDINARY FULLY PAID |
Financials |
$148,744 |
Notification of cessation of securities - NAB
|
27 Feb 2025 8:18AM |
$35.530 |
$48.490 |
risen by
36.48%
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$6,877 |
2024 Full Year Results Announcement
|
27 Feb 2025 8:18AM |
$5.070 |
$4.740 |
fallen by
6.51%
|
|
ALX - Price-sensitive ASX Announcement
Full Release
Key Points
- Statutory net profit after tax of $275.3 million, a 7.4% increase from 2023
- Operating free cash flow rose to $527.1 million, up 16.0%
- Distribution guidance reaffirmed at 20 cents per security for H2 2024 and increased to 40 cents for 2025
- Proportionate toll revenue increased by 5.1% year-over-year
- Successful early achievement of a 25% reduction in scope 1 and 2 emissions by 2025
- 55-year concession agreement signed for motorway A412 in France
- New distribution policy targeting 90-110% of free cash flow introduced
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clearview Wealth Limited (CVW) ORDINARY FULLY PAID |
Financials |
$342 |
CVW Market Release
|
27 Feb 2025 8:18AM |
$0.385 |
$0.545 |
risen by
41.56%
|
|
CVW - Price-sensitive ASX Announcement
Full Release
Key Points
- HY25 life insurance underlying NPAT of $15.2 million, down 22%
- Gross premium income increased by 8% to $191.4 million
- In-force premiums grew by 8% to $387.2 million
- Q1 claims experience was an outlier, causing short-term margin impacts
- NPAT margin normalized to 11% in Q2 FY25 from 4% in Q1
- Company plans to buy back up to 10% of share capital
- Focus on life insurance with exit from wealth management by June 2025
- Technology transformation expected to complete in 1H FY26
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Mach7 Technologies Limited (M7T) ORDINARY FULLY PAID |
Health Care |
$82 |
Half Yearly Report and Accounts
|
27 Feb 2025 8:18AM |
$0.440 |
$0.350 |
fallen by
20.45%
|
|
M7T - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 33% to $17.74 million.
- Loss after tax reduced by 60% to $1.87 million.
- Subscription revenue grew by 59%.
- Operating expenses increased by 15%.
- Strong cash position with $23.60 million available.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Fenix Resources Ltd (FEX) ORDINARY FULLY PAID |
Materials |
$305 |
Change of Director's Interest Notice - J Welborn
|
27 Feb 2025 8:17AM |
$0.290 |
$0.410 |
risen by
41.38%
|
|
| Amcor Plc (AMC) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$32,713 |
425 Ruling - Form 8-K - Launch of consent solicitation
|
27 Feb 2025 8:16AM |
$16.170 |
$70.790 |
risen by
337.79%
|
|
| Amcor Plc (AMC) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$32,713 |
Form 8-K - Launch of consent solicitation
|
27 Feb 2025 8:15AM |
$16.170 |
$70.790 |
risen by
337.79%
|
|
| Heartland Group Holdings Limited (HGH) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Financials |
$990 |
Dividend/Distribution - HGH
|
27 Feb 2025 8:15AM |
$0.825 |
$1.050 |
risen by
27.27%
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$6,877 |
Appendix 4E and 2024 Annual Report
|
27 Feb 2025 8:15AM |
$5.070 |
$4.740 |
fallen by
6.51%
|
|
ALX - Price-sensitive ASX Announcement
Full Release
Key Points
- Net profit after tax increased by 7.4% to A$275.3 million.
- Toll revenue grew by 9% reflecting CPI and GDP-linked increases.
- Corporate governance strengthened with a majority of independent directors.
- Hugh Wehby appointed CEO in November 2024.
- Atlas Arteria joined the United Nations Global Compact.
- The operational performance remained solid despite external challenges.
- Forecast distribution guidance of 40 cents per security for 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
